Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis
Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to...
18-Jul-2019 11:05 AM EDT Add to Favorites
Memorial Sloan Kettering Cancer Center (MSK) announced that the New York State Department of Health has issued an approval for a new molecular assay called Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).
21-Jun-2019 3:00 PM EDT Add to Favorites
Following Milestone FDA Approval, MSK Researchers Address Resistance to Larotrectinib through Next-Generation TRK-Targeted Therapeutic
LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase...
1-Apr-2019 4:05 PM EDT Add to Favorites
During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness.
29-Jan-2019 12:05 PM EST Add to Favorites
Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower...
3-Dec-2018 10:05 AM EST Add to Favorites
MSK experts in CAR-T therapy, immunotherapy, leukemia, lymphoma, blood and marrow stem cell transplantation, and more, are also available to comment on meeting news.
29-Nov-2018 3:05 PM EST Add to Favorites
A randomized clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has shown that fecal microbiota transplants (FMTs)
8-Oct-2018 3:55 PM EDT Add to Favorites
Memorial Sloan Kettering Researchers Build a New Model of Genetically Engineered Immune Cells That May Combat Solid Tumors in the Future
Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.
14-Aug-2018 12:05 PM EDT Add to Favorites
see all news
2-Dec-2014 12:35 PM EST
9-Dec-2013 9:05 AM EST
3-Dec-2013 3:15 PM EST
20-Sep-2013 2:00 PM EDT
12-Mar-2013 6:00 PM EDT
28-Sep-2012 12:40 PM EDTsee all experts